Read by QxMD icon Read


Quentin Perrier, Rachel Tetaz, Magalie Baudrant, Marion Lepelley, Thierry Berney, Pierre-Yves Benhamou, Sandrine Lablanche
No abstract text is available yet for this article.
May 3, 2018: Thérapie
François Krabansky, Brahim Azzouz, Josette Biya, Malak Abou Taam, Aurore Morel, Thierry Trenque
INTRODUCTION: Eosinophilic pneumonia (EP) is a rare but serious adverse drug reaction (ADR) induced by non-steroidal anti-inflammatory drugs (NSAIDs). METHODS: We describe the second published case of EP induced by oral diclofenac. We also reviewed the literature as well as French pharmacovigilance database. Case presentation A 63 year-old woman with polyarthralgia had taken diclofenac for three days for analgesic purposes. Progressively, the patient presented weakness, dyspnea and fever...
April 28, 2018: Thérapie
Mélanie Moltenis, Anne Gondouin, Marie-Blanche Valnet Rabier, Siamak Davani
No abstract text is available yet for this article.
April 23, 2018: Thérapie
Ariane Galaup, Philippe Barthélémy, Brigitte Pouletty-Lefebvre, Jehan-Michel Béhier, Jean Zetlaoui, Thomas Borel
The Leem (French association of pharmaceutical companies) has conducted the eighth survey on attractiveness of France for clinical research. It serves to measure France's global competitiveness for international clinical trials and assess its strengths and areas of excellence. It also highlights the potential for progress and emerging trends at a time when the regulatory environment in France and Europe is undergoing change. This survey has been updated every two years since 2002 using the same methodology...
April 18, 2018: Thérapie
Kassy Raymond Sylvestre Allou, Hinde Iraqi, Yahia Cherrah, Samir Ahid
OBJECTIVES: Do the state of affairs of the perception of free drug samples by a group of prescribers of drugs in the Morocco. METHODS: This was a cross-sectional study of 381 physicians practising in different sectors (public, private) using a self-administered anonymous questionnaire, conducted between December 2016 and March 2017. The questionnaire focused on assessing the general knowledge of prescriber on free drug sample, medical visit of medical representative of pharmaceutical laboratory, drug prescribing and free drug sample use...
April 13, 2018: Thérapie
Claire Kamaliddin, Valentin Joste, Nicolas Argy, Sandrine Houzé
No abstract text is available yet for this article.
April 3, 2018: Thérapie
Virginie Tournay, Antoine Pariente
This article aims at analyzing mechanisms leading to a situation of mistrust about the scientific evaluation of the medicinal product, beyond issues related to links of interests. The assumption is that conflicts of interest are only one component of this mistrust. It doesn't explain all social controversies affecting this sector, in particular the credibility of drug evaluation systems. We explore here how, during the six stages of certification that characterize the trajectory of the drug and its evaluation - the functioning of scientific production and collective representations contribute to this mistrust...
March 30, 2018: Thérapie
Thomas Barré, Florence Vorspan, Maeva Fortias, Marc Veyrier, Pauline Cavagna, Julien Azuar, Louise Nicolas, François Naccache, Hélène Barreteau, Franck Bellivier, Vanessa Bloch
Intranasal naloxone aims at preventing opioid overdose related deaths in active drug users. In France, it has been available since July 2016 through a temporary approval which requires a hospital-based pharmacy and a nominative registration of each patient. We present the characteristics of the first patients who could receive this prescription in our hospital-based addiction center and how they used naloxone during follow-up. Results favor a larger dispensing of naloxone. Patients' as well as peers' and families' education is needed...
March 29, 2018: Thérapie
Quentin Boucherie, Franck Rouby, Diane Frankel, Patrice Roll, Joelle Micallef
Because national data on proton pump inbibitors (PPIs) consumption in France are scarce and because there is a growing literature on potential adverse drug reaction induced by this pharmacological class, we would like to more describe the main evolution of PPI use and the main characteristics of its users in France. We used a 1/97th representative sample of beneficiaries of the French health insurance called "échantillon généraliste des bénéficiaires" (EGB) to describe PPIs' use over time (duration of use by year) from 2006 to 2016...
March 7, 2018: Thérapie
Sibylle de Germay, Maryse Lapeyre-Mestre, Jean-Louis Montastruc, François Montastruc
Anticholinergic drugs (also called antimuscarinics or atropinics) increase the risk of falls, cognitive impairment and/or mortality in older patients. These drugs belong to the lists of potentially inappropriate medications in the elderly. The aim of this review was to present and discuss the different tools available to measure the atropinic risk in drug exposure of older patients. Several scales, developed from biological and/or clinical criteria, allow to classify anticholinergic drugs according to their atropinic potency and to assign to them an atropinic burden...
March 7, 2018: Thérapie
Louise Carton, Nicolas Cabé, Olivier Ménard, Sylvie Deheul, Anne-Sylvie Caous, David Devos, Olivier Cottencin, Régis Bordet
For students, the pressing demands for memorization, top-level performance, and peer competition create an environment favorable for pharmaceutical cognitive doping behavior. We aimed to describe recent practices and the benefit/risk ratio of such behavior and to discuss the issues at stake. The prevalence of pharmaceutical cognitive doping among students has been reported from 1.3% to 33% across studies, with variations depending on country and definition of pharmaceutical cognitive doping. The therapeutic classes most frequently cited as being diverted for doping purposes are psychostimulants and nootropics (methylphenidate, modafinil, piracetam), corticosteroids, sedative drugs and beta-blockers...
March 6, 2018: Thérapie
Quentin Citerne, Sarah Honstettre, Remy Ouichka, Damien Loeuille, Pierre Gillet, Isabelle Chary-Valckenaere
No abstract text is available yet for this article.
March 3, 2018: Thérapie
Neila Fathallah, Nadia Bellasfar, Helmi Ammar, Raoudha Slim, Bouraoui Ouni, Badreddine Sriha, Wissem Hachfi, Chaker Ben Salem
No abstract text is available yet for this article.
March 3, 2018: Thérapie
Michel Tournaire, Emmanuel Devouche, Sylvie Epelboin, Anne Cabau, Annabel Dunbavand, Anne Levadou
OBJECTIVE: Prenatal exposure to diethylstilbestrol (DES) is associated with adverse effects, including genital anomalies and cancers in men and women. Animal studies showed birth defects and tumors in the offspring of mice prenatally exposed to DES. In humans, birth defects, such as hypospadias were observed in children of prenatally exposed women. The aim of this research was to assess the birth defects in children of prenatally exposed men. METHODS: In a retrospective study conceived by a patients' association (Réseau DES France), the reports of men prenatally exposed to DES on adverse health effects in their children were compared with those of unexposed controls and general population...
March 3, 2018: Thérapie
Michaël Rochoy, Christina Zakhem-Stachera, Johana Béné, Christophe Berkhout, Sophie Gautier
OBJECTIVE: Most antidepressants have been associated with a risk of hyponatremia in the literature. This effect is not always reported in monographs. The aim of our study was to clarify the difference of increased risk of hyponatremia among various antidepressants. METHODS: Retrospective study of such cases/non-cases from observations recorded in the French national pharmacovigilance between 01/01/2004 and 31/12/2013. We studied all antidepressants marketed in 2014 in France, with a positive control (haloperidol) and a negative one (amoxicillin)...
March 1, 2018: Thérapie
Amélie Daveluy, Françoise Haramburu
INTRODUCTION: The government plan for the fight against drugs and addictive behaviors 2013-2017 includes several actions concerning French overseas territories, in particular to strengthen information on drug addiction. The Interministerial mission for combating drugs and addictive behaviors (MILD&CA) has commissioned the Bordeaux addictovigilance center to strengthen exchanges on addictovigilance with Réunion Island and Mayotte and to make an inventory of problematic drug use in these two French departments of Indian Ocean...
February 27, 2018: Thérapie
Virginia Neyro, Evelyne Jacqz-Aigrain, Tiphaine Adam de Beaumais
Identification of markers involved in drug disposition is crucial for drugs with a narrow therapeutic index. Individual genomic differences can affect the pharmacology of some drugs and participate to inter-individual variability in drug response. Pharmacogenetics is a useful tool in clinical practice for dosage adjustment and to limit drug toxicities. In pediatrics, physiological changes can also influence the disposition of drugs in infants, children and adolescents. The importance of ontogeny translates into different responses to the same drug in children and adults...
April 2018: Thérapie
Samy Babai, Laurent Auclert, Hervé Le-Louët
BACKGROUND AND AIM: The occurrence of drug induced liver injury (DILI) is the most common reason of post-marketing withdrawals. DILI in humans is difficult to predict using in vitro cytotoxicity screening and animal studies. A review of hepatotoxicity data was performed with the aim of identifying relevant factors that could have predicted the occurrence of serious DILI. METHODS: The drugs withdrawn from the market due to hepatotoxicity in Europe and/or in USA either by marketing authorization holders or by Regulatory agencies from 1997 to 2016 were selected...
February 21, 2018: Thérapie
Carole Piera-Mardemootoo, Philippe Lambert, Jean-Luc Faillie
AIM OF THE STUDY: Metformin is recommended as the first-line treatment of type 2 diabetes mellitus. Despite its common use, few studies have been conducted to precisely measure the efficacy of metformin versus placebo as a first-line treatment. This study aims to assess the precise effects of metformin monotherapy on glycemic control and weight in drug-naive patients with type 2 diabetes mellitus. METHODS: Medline® and Cochrane databases were searched until March 19, 2016 to perform a systematic review and meta-analysis of placebo-controlled randomized trials evaluating metformin monotherapy in drug-naive patients with type 2 diabetes mellitus...
February 21, 2018: Thérapie
Florentia Kaguelidou, Behrouz Kassai Koupai, Genevieve Durrieu
No abstract text is available yet for this article.
February 21, 2018: Thérapie
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"